Outcome variables
The primary endpoint was to assess the efficacy and safety of PCSK9 inhibitors and ANGPTL3 inhibitors in patients with HoFH. Efficacy parameters for PCSK9i (Alirocumab, Evolocumab) and ANGPTL3i (Evonacumab) included changes in lipid profiles, such as total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and lipoprotein levels, including lipoprotein(a) (Lp(a)), apolipoprotein A (Apo-A) and apolipoprotein B (Apo-B). The secondary endpoint focused on safety, with parameters including the prevalence of adverse events (AEs), and inverse variance used for subgroup analyses between groups.